Winning the VAC but Losing the CFO

The Financial Blind Spot in Healthcare

Sometimes our vision of a deal is crystal clear. There is clinical interest. There is a defined need. There are engaged conversations and positive feedback. Head nods turn into internal introductions. From the outside — and often from the inside — it feels like momentum. And yet, months later, the opportunity disappears. Not because the clinical case was weak. Not because the technology lacked value. But because the financial case was never fully aligned. To understand why this happens, it helps to look at the healthcare purchasing process from all sides.

The Hospital’s View: A Structured, Multi-Layered Process

Even in small hospitals or clinics, purchasing medical technology is rarely a single-person decision. Most organizations rely on a cross-functional team to evaluate new devices and software. Often, supply chain leads a Value Analysis Committee (VAC) that includes representatives from supply chain, clinical leadership, physicians, IT, and finance.

At minimum, this group evaluates:

• Clinical Outcomes
• Product Quality and Comparison
• Financial Impact
• Education and Training Requirements
• Integration with Existing Systems

Much of the early research happens independently. Studies consistently show that a significant portion of product evaluation — often cited at 70% or more — occurs through peer conversations, online research, and internal discussions before a sales representative is formally engaged.

Balancing clinical advancement with operational and financial responsibility is complex. The weighting of each evaluation criterion shifts depending on the hospital’s financial health, performance of existing systems, competitive or strategic positioning, capital availability, and whether the product represents a true need versus a “nice to have.”

If the need is validated, the organization may issue an RFP or RFB. At that point, the vendor’s diligence — and the quality of internal relationships — determines whether the opportunity moves forward. From this vantage point, the process appears structured, rational, and collaborative.

The Sales Perspective: Momentum and Advocacy

From a representative’s viewpoint, the beginning of a purchase decision is often hard to define. It might start with an upcoming contract expiration, a conversation at a conference, a discussion about future projects, or an established relationship.

Regardless of how it begins, discovery defines the trajectory of the opportunity. In healthcare, depending on complexity and capital requirements, the buying cycle for devices and software can stretch anywhere from six to twenty-four months. During this time, most representatives focus appropriately on understanding motivating clinical factors, positioning features and benefits, differentiating from competitors, and building relationships across departments.

When department leaders are enthusiastic and willing to introduce the representative to others in the decision loop, it feels like progress. When internal advocates speak positively about the solution, confidence grows. At that moment, it can feel like the deal is as good as done. But this is where many opportunities quietly unravel.

A warm circle of clinical supporters does not guarantee organizational approval. Because the final sign-off rarely lives where the initial enthusiasm begins.

The Financial Lens: Where Deals Are Truly Tested

As recommendations move up the chain of authority, the lens changes. Excitement is replaced by scrutiny. Clinical enthusiasm meets capital allocation discipline. Innovation enters a risk framework.

When a vendor representative — or even a clinical champion — presents a compelling innovation story, they are often stepping into a financial environment defined by caution. That does not mean the organization does not want the technology. It means they are evaluating risk differently.

The proposed solution is competing against other capital equipment needs, IT investments, facility upgrades, etc. Finance is not evaluating enthusiasm. They are evaluating timing, structure, and risk. This is the point at which many otherwise strong opportunities stall — not because the clinical case lacked merit, but because the financial context was not fully understood.

The Blind Spot

One of the most common missed variables in healthcare sales today is not clinical value. It is financial alignment. A representative may have done excellent discovery within departments. They may understand workflow pain points and outcome improvements. They may have built strong relationships and internal sponsorship. Yet, critical financial considerations were never fully surfaced:

• Is this already in the capital plan?
• Where does it rank among competing priorities?
• Is cash preserve currently a strategic focus?
• Would an alternative acquisition structure change the decision timeline?
• Who ultimately bears responsibility for approval — CFO, System committee, board?

When these conversations occur late — after enthusiasm has built — they often introduce friction that feels unexpected. From finance’s perspective, however, these are foundational questions, not obstacles. Understanding how the customer buys is just as important as understanding why they buy.

Moving from Product Presentation to Organizational Alignment

The strongest healthcare sales professionals do not replace the clinical value story — they support it with financial fluency. That means exploring questions such as:

• How have similar projects been aquired in the past?
• Is this currently included in the fiscal capital plan?
• What other major capital projects are under consideration this year?
• Who ultimately signs off on this type of purchase?
• Would an operating or alternative financing structure accelerate approval?
• What are the financial consequences of maintaining the status quo?
• How can we help prepare or strengthen the presentation of finance?

These conversations are not about pushing financing mechanisms. They are about understanding the organizational environment. When financial decision-makers feel that risk, structure, and timing have been considered thoughtfully — not reactively — the tone of the conversation changes. The proposal shifts from being “another request for capital” to being a solution that aligns with broader strategic and financial realities.

Seeing the Whole Picture

Healthcare organizations today are balancing two equally critical mandates: deliver excellent patient care and maintain financial stability. Clinical leaders naturally focus on outcomes and workflow. Financial leaders must focus on sustainability and risk. Neither perspective is wrong. Both are essential. A deal that appears crystal clear at the department level can look very different through a financial lens. The organizations — and representatives — who consistently succeed are those who anticipate financial questions early, align with capital planning cycles, understand competitive internal priorities, structure proposals in ways that reduce perceived risk, and help internal sponsors navigate the approval process. In doing so, they move beyond presenting products. They begin solving internal problems. And in today’s healthcare environment, that difference can determine whether a proposal advances — or quietly fades.